Electronic Acknowledgement Receipt				
EFS ID:	3834112			
Application Number:	10007459			
International Application Number:				
Confirmation Number:	3774			
Title of Invention:	Inhibition of gene expression by delivery of small interfering RNA to post- embryonic animal cells in vivo			
First Named Inventor/Applicant Name:	David L. Lewis			
Customer Number:	25032			
Filer:	Kirk E. Ekena			
Filer Authorized By:				
Attorney Docket Number:	Mirus.030.04			
Receipt Date:	25-AUG-2008			
Filing Date:	07-NOV-2001			
Time Stamp:	16:08:40			
Application Type:	Utility under 35 USC 111(a)			
Payment information:				

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$655
RAM confirmation Number	1456
Deposit Account	
Authorized User	

File Listing:

Document Doc Number	ument Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
------------------------	-------------------	-----------	-------------------------------------	---------------------	---------------------

1	Miscellaneous Incoming Letter	transmittal_sb-21.pdf	211183	no	1
			b4d7d420f1d9eb6592d827f524ef654aa0b 3010b		
Warnings:					
Information:					r
2		30_04-amend-7.pdf	106577	yes	3
			9399bc73640cceb338345b2e84cb5bfe857 51318		
	Multip	art Description/PDF files in	n .zip description		
	Document Description		Start	End	
	Amendment - After Non-Final Rejection		1	1	
	Claims		2	2	
	Applicant Arguments/Remarks Made in an Amendment 3			3	
Warnings:					
Information:					
3	Request under Rule 48 correcting	30_04-CFR-1_48.pdf	103313	no	2
	inventorship		2b93101869263d2398c1084140f1a8fc63f4 5e84		
Warnings:					
Information:		<u> </u>	1		ı
4	Rule 130, 131 or 132 Affidavits	30_04-Budker.pdf	90925	no	1
			ff45bee81b1526cbe0ca305b81971681d73 72a79		
Warnings:					
Information:		<u> </u>	1		ı
5	Oath or Declaration filed	30_04-Declaration.pdf	457410	no	4
			dd20a8916621688b6a99f6ab982bdd0aa5c f623b		
Warnings:					
Information:					
6	Rule 130, 131 or 132 Affidavits	30_04_Decl-131.pdf	2601102	no	14
0			a801b475ca58ec367670777417745303808 2817b		
Warnings:					
Information:					
7	Extension of Time	extension_of_time.pdf	177734	no	1
′	Extension of time		27b5245bf94062e4f5a1814e10b8ddb8375 85351		
Warnings:					
Information:					

8	Fee Worksheet (PTO-06)	fee-info.pdf	32175	no	,
	ree worksheet (170 day	·	be43197f5d4360fb2969608536474c076f47 70f6		
Warnings:					
Information:					
		Total Files Size (in bytes):	(in bytes): 3780419		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.